These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 32717027)

  • 1. Mullally A, Hood J, Harrison C, Mesa R. Fedratinib in myelofibrosis. Blood Adv. 2020;4(8):1792-1800.
    Blood Adv; 2020 Jul; 4(14):3315. PubMed ID: 32717027
    [No Abstract]   [Full Text] [Related]  

  • 2. Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Jourdan E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Tang D; Abraham P; Lord-Bessen J; Rose S; Guo S; Liao W; Mesa RA
    Hemasphere; 2021 May; 5(5):e562. PubMed ID: 33969275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
    Mesa RA; Schaap N; Vannucchi AM; Kiladjian JJ; Passamonti F; Zweegman S; Talpaz M; Verstovsek S; Rose S; Abraham P; Lord-Bessen J; Tang D; Guo S; Ye X; Harrison CN
    Hemasphere; 2021 May; 5(5):e553. PubMed ID: 33969273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis.
    Bewersdorf JP; Jaszczur SM; Afifi S; Zhao JC; Zeidan AM
    Cancer Manag Res; 2019; 11():10777-10790. PubMed ID: 31920387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fedratinib Becomes New Option in Myelofibrosis.
    Cancer Discov; 2019 Oct; 9(10):1332. PubMed ID: 31471287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulatory saga of fedratinib.
    Khal S; Prasad V; Palumbo A
    J Oncol Pharm Pract; 2021 Jul; 27(5):1248-1250. PubMed ID: 34013823
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Tang C; Niu X; Shi L; Zhu H; Lin G; Xu RA
    Front Pharmacol; 2020; 11():626897. PubMed ID: 33613287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erratum for the Research Article: "CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo" by P. J. Hanley, J. J. Melenhorst, S. Nikiforow, P. Scheinberg, J. W. Blaney, G. Demmler-Harrison, C. R. Cruz, S. Lam, R. A. Krance, K. S. Leung, C. A. Martinez, H. Liu, D. C. Douek, H. E. Heslop, C. M. Rooney, E. J. Shpall, A. J. Barrett, J. R. Rodgers, C. M. Bollard.
    Sci Transl Med; 2016 Jan; 8(321):321er1. PubMed ID: 26764153
    [No Abstract]   [Full Text] [Related]  

  • 9. Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.
    Roskoski R
    Pharmacol Res; 2020 Feb; 152():104609. PubMed ID: 31862477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction to: Why Our Long-Term Functional Prognosis Tools Are a Valuable Contribution to the Traumatic Brain Injury Outcome Literature: Response to Foks et al. by Walker, W.C., Sima, A.P., Hoffman, J.M., Harrison-Felix, C., Agyemang, A.A., Stromberg, K.A., Marwitz, J.H., Brown, A.W., Graham, K.M., Merchant, R., and Kreutzer, J.S. J. Neurotrauma 2019;36(8):1384-1385. (DOI: 10.1089/neu.2018.6069).
    J Neurotrauma; 2020 Mar; 37(6):904. PubMed ID: 32155391
    [No Abstract]   [Full Text] [Related]  

  • 11. Correction to: Predicting Long-Term Global Outcome after Traumatic Brain Injury: Development of a Practical Prognostic Tool Using the Traumatic Brain Injury Model Systems National Database by Walker, W.C., Stromberg, K.A., Marwitz, J.H., Sima, A.P., Agyemang, A.A., Graham, K.M., Harrison-Felix, C., Hoffman, J.M., Brown, A.W., Kreutzer, J.S., and Merchant, R. J. Neurotrauma 2018;35(14):1587-1594. (DOI: 10.1089/neu.2017.5359).
    J Neurotrauma; 2020 Mar; 37(6):905. PubMed ID: 32155392
    [No Abstract]   [Full Text] [Related]  

  • 12. Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the
    Liu LW; Hsieh YY; Yang PM
    J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32947833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gowin K, Ballen K, Ahn KW, et al. Survival following allogeneic transplant in patients with myelofibrosis. Blood Adv. 2020;4(9):1965-1973.
    Blood Adv; 2021 Jul; 5(13):2751. PubMed ID: 34242390
    [No Abstract]   [Full Text] [Related]  

  • 14. [Characteristics and the prevalence of respiratory viruses and the correlation with climatic factors of hospitalized children in Suzhou children's hospital].
    Ji W; Chen ZR; Guo HB; Wang MJ; Yan YD; Zhang XL; Ding YF
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Mar; 45(3):205-10. PubMed ID: 21624230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a soluble TGF-beta receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy.
    Zhang M; Berndt BE; Chen JJ; Kao JY
    J Immunol; 2008 Sep; 181(5):3690-7. PubMed ID: 18714045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-center evaluation of the adenovirus R-gene US assay for the detection of adenovirus in respiratory samples.
    Manji R; Zheng X; Patel A; Kowerska M; Vossinas M; Drain A; Todd KM; Lenny N; DeVincenzo JP; Ginocchio CC
    J Clin Virol; 2014 Jun; 60(2):90-5. PubMed ID: 24768208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JCCA 2006;50 (3):172-181. Oakley P, Harrison DD, Harrison DE, Haas J. A rebuttal to chiropractic radiologists' view of the 50 year old, linear-no-threshold radiation risk model (commentary).
    Bussières AE; Ammendolia C; Peterson C; Taylor JA
    J Can Chiropr Assoc; 2006 Dec; 50(4):285-6; author reply 286-8. PubMed ID: 17549190
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: JCCA 2006;50 (3):172-181. Oakley P, Harrison DD, Harrison DE, Haas J. A rebuttal to chiropractic radiologists' view of the 50 year old, linear-no-threshold radiation risk model (commentary).
    McCoy M
    J Can Chiropr Assoc; 2007 Mar; 51(1):61. PubMed ID: 17657293
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of Myelofibrosis: from Diagnosis to New Target Therapies.
    Iurlo A; Cattaneo D; Bucelli C
    Curr Treat Options Oncol; 2020 Apr; 21(6):46. PubMed ID: 32350623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.
    Marcellino BK; Verstovsek S; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):415-421. PubMed ID: 32199764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.